Ph.D., Carnegie Mellon University, Statistics, 1990.
M.S., Carnegie Mellon University, Statistics, 1987.
B.S., University of Cape Town, Statistics, 1985.
Methods for evaluating diagnostic tests
Modeling and outcomes research in prostate cancer
Modeling impact of PSA screening and other interventions on prostate cancer incidence and mortality
Costs and benefits of prostate cancer screening
Trends in prostate cancer screening and related behaviors
Dr. Ruth (Douglas) Etzioni is a Full Member in Biostatistics of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center. Her work focuses on the development and implementation of statistical methods for prostate cancer studies. In the past, she has worked on assessing the efficacy of PSA screening from population studies, estimating the frequency of overdiagnosis associated with PSA, evaluating novel prostate cancer biomarkers, and tracking patterns and outcomes of prostate cancer care. Her work in prostate cancer surveillance is conducted as part of the Cancer Intervention and Surveillance Modeling Network (CISNET).
As leader of the biostatistics core for the Northwest Prostate Cancer SPORE, Dr. Etzioni has developed methods for analyzing immunohistochemical studies, and combining results from microarray experiments, while working with SPORE investigators to select the most appropriate design and analysis approaches for a broad array of studies. She is an affiliate investigator on the Data Management Coordination Center for the Early Detection Research Network (EDRN) and continues to work with EDRN statisticians on methods for biomarker development. In addition to these projects, her current interests include modeling the development of resistance to androgen ablation therapy.
American Statistical Association
Institute of Mathematical Statistics
International Biometric Society
Society for Medical Decision Making
Predictors of preoperative MRI for breast cancer: differences by data source.. Journal of comparative effectiveness research. :1-12.. 2015.
Measures of survival benefit in cancer drug development and their limitations.. Urologic oncology. 33(3):122-7.. 2015.
Effect of Screening Mammography on Cancer Incidence and Mortality.. JAMA internal medicine.. 2015.
Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs.. Medical decision making : an international journal of the Society for Medical Decision Making.. 2015.
Models in the development of clinical practice guidelines.. Annals of internal medicine. 162(7):530-1.. 2015.
Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 24(4):677-82.. 2015.
Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study.. Annals of internal medicine. 160(9):594-602.. 2014.
Oversimplifying Overdiagnosis.. Journal of general internal medicine.. 2014.
RE: A Model Too Far.. Journal of the National Cancer Institute.. 2014.
Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials.. Journal of the National Cancer Institute.. 2014.
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.. Annals of internal medicine. 161(2):104-12.. 2014.
Overdiagnosis and Overtreatment of Prostate Cancer.. European urology.. 2014.
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. International journal of cancer. Journal international du cancer.. 2014.
Individualized estimates of overdiagnosis in screen-detected prostate cancer.. Journal of the National Cancer Institute. 106(2):djt367.. 2014.
Models in the development of clinical practice guidelines.. Annals of internal medicine. 161(11):812-8.. 2014.
A reality check for overdiagnosis estimates associated with breast cancer screening.. Journal of the National Cancer Institute. 106(12). 2014.
Biological correlates of biochemical recurrence free survival using multiple markers in a large tissue microarray cohort.. Annals of clinical and laboratory science. 43(1):11-21.. 2013.
Advanced diagnostic breast cancer imaging: variation and patterns of care in washington state.. Journal of oncology practice / American Society of Clinical Oncology. 9(5):e194-202.. 2013.
Modeling grade progression in an active surveillance study.. Statistics in medicine.. 2013.
Early Detection of Prostate Cancer: AUA Guideline.. The Journal of urology.. 2013.
Alternative prostate cancer screening strategies--in response.. Annals of internal medicine. 158(10):778-9.. 2013.